A promising diabetes drug treatment could reach stage three clinical trials this year. Glenmark Pharmaceuticals claimed this week that their experimental new diabetes treatment molecule, known as meloglipti, will reach last-stage clinical trials by the end of 2009.
Glycaemic control amongst patients with type 2 diabetes mellitus has been proved efficient at phase IIb level clinical trials. The company used a 12-week study of 494 patients. The results showed low incidences of hypoglycaemia and a neutral influence on body weight .
Glenmark, who are based in Mumbai, India, will continue to look for partners with whom to outlicence the product. The company ended a deal with Merck last year, as the German pharmaceutical giant exits diabetes research .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…